Endosialin: from vascular target to biomarker for human sarcomas

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Hodgson DR, Whittaker RD, Herath A, Amakye D, Clack G: Biomarkers in oncology drug development. Mol. Oncol.3,24–32 (2009).
  Medline CASGoogle Scholar
• 2  Atkinson AJ, Colburn WA, DeGruttola VG et al.: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69,89–95 (2001).
  MedlineGoogle Scholar
• 3  Dhani N, Siu LL: Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Cancer Metastasis Rev.27,339–349 (2008).
  Medline CASGoogle Scholar
• 4  Kelloff GJ, Bast RC, Coffey DS et al.: Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment. Clin. Cancer Res.10,3881–3884 (2004).
  Medline CASGoogle Scholar
• 5  McShane LM, Hunsberger S, Adjei AA: Effective incorporation of biomarkers into Phase II trials. Clin. Cancer Res.15(6),1898–1905 (2009).
  Medline CASGoogle Scholar
• 6  Williams SA, Singh P, Isaacs JT, Denmeade SR: Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate67(3),312–329 (2006).
  CASGoogle Scholar
• 7  Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EVS, Hansen HH: Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin. Oncol.22,4051–4058 (2004).
  MedlineGoogle Scholar
• 8  Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effective analysis. J. Clin. Oncol.22(5),854–863 (2004).
  MedlineGoogle Scholar
• 9  Dowsett M, Dumbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res.14(24),8019–8026 (2008).
  Medline CASGoogle Scholar
• 10  Alitalo K, tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature438,946–953 (2005).
  Medline CASGoogle Scholar
• 11  Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature438,967–974 (2005).▪ Review of the angiogenesis process and antiangiogenic therapeutics.
  Medline CASGoogle Scholar
• 12  Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5),1011–1027 (2005).
  Medline CASGoogle Scholar
• 13  Rettig W, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. PNAS89,10832–10836 (1992).▪ First recognition of endosialin in human cancer.
  Medline CASGoogle Scholar
• 14  Christian S, Ahorn H, Koehler A et al.: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J. Biol. Chem.276(10),7408–7414 (2001).
  Medline CASGoogle Scholar
• 15  Conway EM, Van de Wouwer M, Pollefeyt S et al.: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways. J. Exp. Med.196(5),565–577 (2002).
  Medline CASGoogle Scholar
• 16  Greenlee MC, Sullivan SA, Bohlson SS: CD93 and related family members: their role in innate immunity. Curr. Drug Targets9(20),130–138 (2008).
  Medline CASGoogle Scholar
• 17  Van de Wouwer M, Conway EM: Novel functions of thrombomodulin in inflammation. Crit. Care Med.32(5),S254–S261 (2004).
  Medline CASGoogle Scholar
• 18  Hanly AM, Winter DC. The role of thrombomodulin in malignancy. Semin. Thromb. Hemost.33,673–679 (2007).
  Medline CASGoogle Scholar
• 19  Lager DJ, Callaghan EJ, Worth SF, Raife TJ, Lentz SR: Cellular localization of thrombomodulin in human epithelial squamous malignancies. Am. J. Pathol.146(4),933–943 (1995).
  Medline CASGoogle Scholar
• 20  Tarr J, Eggleton P: Immune function of C1q and its modulators CD91 and CD93. Crit. Rev. Immunol.25(4),305–330 (2005)
  Medline CASGoogle Scholar
• 21  Lu JH, The BK, Wang L et al.: The classical and regulatory functions of C1q in immunity and autoimmunity. Cell. Mol. Immunol.5(1),9–21 (2008).
  Medline CASGoogle Scholar
• 22  Opavsky R, Haviernik P, Jurkovicova D et al.: Molecular characterization of the mouse TEM1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J. Biol. Chem.276(42),38795–38807 (2001).
  Medline CASGoogle Scholar
• 23  Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KK, St Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res.61,6649–6655 (2001).
  Medline CASGoogle Scholar
• 24  Nanda A, Karim B, Peng Z et al.: Tumor endothelial marker 1 (Tem 1) functions in the growth and progression of abdominal tumors. Proc. Natl Acad. Sci. USA103(9),3351–3356 (2006).▪▪ Describes tumor challenge in knockout mice lacking endosialin.
  Medline CASGoogle Scholar
• 25  Harris AL: Hypoxia – a key regulatory factor in tumour growth. Nat. Rev. Cancer2,38–47 (2002).
  Medline CASGoogle Scholar
• 26  Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev.26,281–290 (2007).
  Medline CASGoogle Scholar
• 27  Ohradanova A, Gradin K, Barathova M et al.: Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br. J. Cancer99,1348–1356 (2008).
  Medline CASGoogle Scholar
• 28  Tomkowicz B, Rybinski K, Foley B et al.: Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc. Natl Acad. Sci. USA104(46),17965–17970 (2007).
  Medline CASGoogle Scholar
• 29  Becker R, Lenter MC, Vollkommer T et al.: Tumor stroma marker endosialin (Tem 1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J.22,3059–3067 (2008).
  Medline CASGoogle Scholar
• 30  Iacobelli S, Sismondi P, Giai M et al.: Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br. J. Cancer69,172–176 (1994).
  Medline CASGoogle Scholar
• 31  Marchetti A, Tinari N, Buttitta F et al.: Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res.62,2535–2539 (2002).
  Medline CASGoogle Scholar
• 32  Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer2,727–739 (2002).
  Medline CASGoogle Scholar
• 33  St. Croix B, Rago C, Velculescu V et al.: Genes expressed in human tumor endothelium. Science289,1197–1202 (2000).
  Medline CASGoogle Scholar
• 34  Nanda A, St. Croix B: Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol.16,44–49 (2004).
  Medline CASGoogle Scholar
• 35  Teicher BA: Newer vascular targets: endosialin (review). Int. J. Oncol.30,305–312 (2007).
  Medline CASGoogle Scholar
• 36  Brady J, Neal J, Sadakar N, Gasque P: Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J. Neuropathol. Exp. Neurol.63(12),1274–1283 (2004).
  Medline CASGoogle Scholar
• 37  Madden SL, Cook BP, Nacht M et al.: Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol.165(2),601–608 (2004).
  Medline CASGoogle Scholar
• 38  Asahara T, Masuda H, Takahashi T et al.: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res.85,221–228 (1999).
  Medline CASGoogle Scholar
• 39  Duda D, Cohen K, Kozin S et al.: Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood107,2774–2776 (2006).
  Medline CASGoogle Scholar
• 40  Lyden D, Hattori K, Dias S et al.: Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med.7,1194–1201 (2001).
  Medline CASGoogle Scholar
• 41  Goa D, Nolan DJ, Mellick AS et al.: Endothelial progenitor cells control the angiogenic switch in lung mouse metastasis. Science319,195–198 (2008).
  MedlineGoogle Scholar
• 42  Shirakawa K, Shibuya M, Heike Y et al.: Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int. J. Cancer99,344–351 (2002).
  Medline CASGoogle Scholar
• 43  Bian X, Du L, Shi J et al.: Correlation of bGF, FGFR-1, and VEGF expression with vascularity and malignancy of human astrocytomas. Anal. Quant. Cytol. Histol.22,267–274, (2000).
  Medline CASGoogle Scholar
• 44  Zhang H, Vakil V, Braunstein M et al.: Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood105(8),3286–3294 (2005).
  Medline CASGoogle Scholar
• 45  Dome B, Timar J, Dobos J et al.: Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res.66,7341–7347 (2006).
  Medline CASGoogle Scholar
• 46  Peters B, Diaz L, Polyak K et al.: Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med.11,261–262 (2005).
  Medline CASGoogle Scholar
• 47  Bagley RG, Rouleau C, St. Martin T et al.: Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol. Cancer Ther.7(8),2536–2546 (2008).
  Medline CASGoogle Scholar
• 48  Conejo-Garcia JR, Buckanovich RJ, Benencia F et al.: Vascular leukocytes contribute to tumor vascularization. Blood105(2),679–681 (2005).
  Medline CASGoogle Scholar
• 49  Naik RP, Jin D, Chuang E et al.: Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res. Treat.107(1),133–138 (2008).
  MedlineGoogle Scholar
• 50  Yu D, Sun X, Qiu Y et al.: Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin. Cancer Res.13(13),3814–3824 (2007).
  Medline CASGoogle Scholar
• 51  Bogos K, Renyi-Vamos F, Ddobos J et al.: High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin. Cancer Res.15(5),1741–1746 (2009).
  Medline CASGoogle Scholar
• 52  Zheng PP, Hop WC, Luider TM et al.: Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann. Neurol.62,40–48 (2007).
  Medline CASGoogle Scholar
• 53  Donate F, Juarex JC, Burnett ME et al.: Identification of biomarkers for the antiangiogenic and antitumour activity of superoxide dismutatase (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br. J. Cancer98(4),776–783 (2008).
  Medline CASGoogle Scholar
• 54  Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat. Rev.6,835–845 (2006).
  CASGoogle Scholar
• 55  Shaked Y, Ciarrocchi A, Franco M et al.: Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science313(5794),1785–1787 (2006).
  Medline CASGoogle Scholar
• 56  Hirschi KK, D’Amore PA: Pericytes in the microvasculature. Cardiovasc. Res.32,687–698 (1996).
  Medline CASGoogle Scholar
• 57  Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs169,1–11 (2001).
  Medline CASGoogle Scholar
• 58  Bagley RG, Honma N, Weber W et al.: Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc. Res.76,280–288 (2008).▪ Describes endosialin, pericytes and transgenic mice expressing human endosialin.
  Google Scholar
• 59  Simonavicius N, Robertson D, Bax, DA, Jones C, Huijbers IJ, Isacke CM: Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade gliomas. Mod. Pathol.21(3) 308–315 (2008).
  Medline CASGoogle Scholar
• 60  MacFadyen J, Savage K, Wienke D, Isacke CM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr. Patterns7,363–369 (2007).
  Medline CASGoogle Scholar
• 61  Rupp C, Dolznig H, Puri C et al.: Mouse endosialin, a C-type lectin-like surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun.6,10–21 (2006).
  MedlineGoogle Scholar
• 62  Christian S, Winkler R, Helfrich I et al.: Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am. J. Pathol.172(2),486–494 (2008).
  Medline CASGoogle Scholar
• 63  MacFadyen JR, Haworth O, Robertson D et al.: Endosialin (TEM 1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett.579,2569–2575 (2005).
  Medline CASGoogle Scholar
• 64  Rupp C, Dolznig H, Puri C et al.: Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn. Mol. Pathol.15(1),35–42 (2006).
  Medline CASGoogle Scholar
• 65  Huber MA, Kraut N, Schweifer N et al.: Expression of stromal cell markers in distinct compartments of human skin cancers. J. Cutan. Pathol.33,145–155 (2006).
  MedlineGoogle Scholar
• 66  Lax S, Hou TZ, Jenkinson E et al.: CD248/endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair. FEBS Lett.581,3550–3556 (2007).
  Medline CASGoogle Scholar
• 67  Dolznig H, Schweifer N, Puri C et al.: Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun.5,10 (2005).
  MedlineGoogle Scholar
• 68  Bagley RG, Weber W, Rouleau C et al.: Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int. J. Oncol.34,619–627 (2009).
  Medline CASGoogle Scholar
• 69  Karnoub AE, Dash AB, Vo AP et al.: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature449,557–565 (2007).▪ Describes mesenchymal stem cell involvement in tumor development and metastasis.
  Medline CASGoogle Scholar
• 70  Marty C, Langer-Machova Z, Sigrist S, Schott H, Schwendener RA, Ballmer-Hofer K: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Lett.235,298–308 (2006).
  Medline CASGoogle Scholar
• 71  Davies G, Rmali KA, Watkins G, Mansel RE, Mason MD, Jiang WG: Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance. Int. J. Oncol.29,1311–1317 (2006).
  Medline CASGoogle Scholar
• 72  Rmali KA, Puntis MCA, Jiang WG: Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J. Gastroenterol.11(9),1283–1286 (2005).
  Medline CASGoogle Scholar
• 73  Rouleau C, Curiel M, Weber W et al.: Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin. Cancer Res.14(22),7223–7236 (2008).▪▪ Extensive survey of endosialin expression in human carcinoma specimens.
  Medline CASGoogle Scholar
• 74  Ishida I, Tomizuka K, Yoshida H et al.: Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells4(1),91–102 (2002).
  Medline CASGoogle Scholar
• 75  Tomizuka K, Shinohara T, Yoshida H et al.: Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and k loci and expression of fully human antibodies. Proc. Natl Acad. Sci. USA97(2),722–727 (2000).
  Medline CASGoogle Scholar
• 76  Gibbs CP, Kukekov VG, Reith JD et al.: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia7(11),967–976 (2005).
  Medline CASGoogle Scholar
• 77  Fujii H, Honoki K, Tsujiuchi T et al.: Reduced expression of INK4a/ARF genes in stem-like sphere cells from rat sarcomas. Biochem. Biophys. Res. Commun.362,773–778 (2007).
  Medline CASGoogle Scholar
• 78  Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol.34(5),1381–1386 (2009).
  Medline CASGoogle Scholar
• 79  Kasper B, Gil T, D’Hondt V, Gebhart M, Awada A: Novel treatment strategies for soft tissue sarcoma. Crit. Rev. Oncol. Hematol.62,9–15 (2007).
  MedlineGoogle Scholar
• 80  Schuetze SM. Chemotherapy in the management of osteosarcoma and Ewing’s sarcoma. J. Natl Compr. Canc. Netw.5,449–455 (2007).
  Medline CASGoogle Scholar
• 81  Kasper B, Gil T, Awada A: Chemotherapy in the management of osteosarcoma and Ewing’s sarcoma: disappointment or challenge? Curr. Opin. Oncol.19,336–340 (2007).
  Medline CASGoogle Scholar
• 82  Loges S, Roncal C, Carmeliet P: Development of targeted angiogenic medicine. J. Thromb. Haemost.7,21–33 (2009).
  Medline CASGoogle Scholar
• 83  Jain RK, Duda DG, Sorensen AG: Emerging paradigms and potential biomarkers of response and resistance in antiangiogenic therapy of cancer. In: ASCO Educational Book.716–721 (2009).
  Google Scholar
• 101  Becker R, Augustin HG: CD248. Atlas of genetics and cytogenetics in oncology and haematology (2008). http://AtlasGeneticsOncology.org/Genes/CD248ID968ch11q13.html
  Google Scholar